EUROPE CRISPR MARKET FORECAST 2018-2026
KEY FINDINGS
The Europe CRISPR market is anticipated to evolve with 35.19% CAGR over the forecast period of 2018-2026. The revenue generated by this market is expected to increase from $120 million and reach $1817 million over this forecasted period.
MARKET INSIGHTS
U.K market dominated the Europe CRISPR market in 2017 and is expected to continue its dominance throughout the forecast period. Gowing stem cell research in the region is significantly aiding the market growth. Germany implies strict liability for contamination with GMOs, and has tough, strict and methodically enforced regulations over the release of GMOs into the market. On the other hand, the law on Biomedical Research in Spain allows research on embryos, but for therapeutic purposes only. In France, some laws like the Law on Bioethics 2004 and 2011 restricts the use of human embryos and embryonic stem cells for research until proper regulatory conditions are met.
COMPETITIVE INSIGHTS
Companies like Novartis International Ag, New England Biolabs Inc, Lonza Group Ag,Venture Capital Funding, Precision Biosciences, Sigma-Aldrich (Merck), Thermo Fisher Scientific, Sangamo Biosciences Inc, Integrated DNA Technologies (IDT), Cellectis Bioresearch Sas, Horizon Discovery Plc, and Editas Medicine have strongly established themselves in this market.
The Europe CRISPR market is anticipated to evolve with 35.19% CAGR over the forecast period of 2018-2026. The revenue generated by this market is expected to increase from $120 million and reach $1817 million over this forecasted period.
MARKET INSIGHTS
U.K market dominated the Europe CRISPR market in 2017 and is expected to continue its dominance throughout the forecast period. Gowing stem cell research in the region is significantly aiding the market growth. Germany implies strict liability for contamination with GMOs, and has tough, strict and methodically enforced regulations over the release of GMOs into the market. On the other hand, the law on Biomedical Research in Spain allows research on embryos, but for therapeutic purposes only. In France, some laws like the Law on Bioethics 2004 and 2011 restricts the use of human embryos and embryonic stem cells for research until proper regulatory conditions are met.
COMPETITIVE INSIGHTS
Companies like Novartis International Ag, New England Biolabs Inc, Lonza Group Ag,Venture Capital Funding, Precision Biosciences, Sigma-Aldrich (Merck), Thermo Fisher Scientific, Sangamo Biosciences Inc, Integrated DNA Technologies (IDT), Cellectis Bioresearch Sas, Horizon Discovery Plc, and Editas Medicine have strongly established themselves in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. ROE (REST OF EUROPE)
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. ROE (REST OF EUROPE)
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
LIST OF TABLES
TABLE 1 EUROPE CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 3 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 4 EUROPE CRISPR MARKET IN PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 5 TOOLS NAME AND THEIR PROVIDERS
TABLE 6 EUROPE CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 7 EUROPE CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 8 EUROPE CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 9 EUROPE CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 10 EUROPE CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 11 EUROPE CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 12 EUROPE CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 13 EUROPE CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 14 EUROPE CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 15 EUROPE CRISPR MARKET BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 16 EUROPE CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 17 EUROPE CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 18 EUROPE CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 19 EUROPE CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 20 EUROPE CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 21 EUROPE CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 22 EUROPE CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 23 EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
TABLE 1 EUROPE CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 3 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 4 EUROPE CRISPR MARKET IN PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 5 TOOLS NAME AND THEIR PROVIDERS
TABLE 6 EUROPE CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 7 EUROPE CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 8 EUROPE CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 9 EUROPE CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 10 EUROPE CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 11 EUROPE CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 12 EUROPE CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 13 EUROPE CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 14 EUROPE CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 15 EUROPE CRISPR MARKET BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 16 EUROPE CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 17 EUROPE CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 18 EUROPE CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 19 EUROPE CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 20 EUROPE CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 21 EUROPE CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 22 EUROPE CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 23 EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
LIST OF FIGURES
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 EUROPE CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 EUROPE CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 EUROPE CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 EUROPE CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 EUROPE CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 EUROPE CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 EUROPE CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 EUROPE CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 EUROPE CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 EUROPE CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 EUROPE CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 EUROPE CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 EUROPE CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 EUROPE CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 EUROPE CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 EUROPE CRISPR MARKET SHARE BY REGION 2016
FIGURE 20 EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 21 UNITED KINGDOM CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 22 FRANCE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 GERMANY CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 24 SPAIN CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 25 ITALY CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 26 REST OF EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 27 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 EUROPE CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 EUROPE CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 EUROPE CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 EUROPE CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 EUROPE CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 EUROPE CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 EUROPE CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 EUROPE CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 EUROPE CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 EUROPE CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 EUROPE CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 EUROPE CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 EUROPE CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 EUROPE CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 EUROPE CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 EUROPE CRISPR MARKET SHARE BY REGION 2016
FIGURE 20 EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 21 UNITED KINGDOM CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 22 FRANCE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 GERMANY CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 24 SPAIN CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 25 ITALY CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 26 REST OF EUROPE CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 27 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
